Emcure Pharmaceuticals Ltd share price slipped 0.91% to Rs 1959.1. The Company's net profit saw a strong growth of 20% to Rs 292.49 crore, while revenue from operations slightly gained 4.48% to Rs 2580.45 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.84 lakh crore, easing 5.15%. It has inched up 1.03% over last one week and advanced by 11.63% in last one month while the market capitalization of Emcure Pharmaceuticals Ltd has improved by 2.57% and 19.40% in the same period respectively. Profit before tax (PBT) of Emcure Pharmaceuticals Ltd stood at Rs 393.53 crore in Q2 FY26, jumping 35.35% year-on-year, and rallying 15.34% quarter-on-quarter. EBITDA came in at Rs 530 crore, expanding by 28.41% YoY and rising by 11.54% sequentially. Total expenses grew marginally by 2.91% to Rs 2157.46 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 481.14 crore, rising 14.95% YoY, while employee benefits expense was at Rs 409.5 crore, inching up 5.87% YoY. For the TTM ended FY26, revenue from operations grew 18.59% to Rs 7896.0 crore, while net profit jumped 34.10% to Rs 707.47 crore, compared to previous TTM. EBITDA surged by 124346% to Rs 1407.12 crore, and PBT witnessed a strong rise of 33.57% to Rs 971.35 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 851.71 crore in FY26, as against Rs 1097.24 crore in FY25. Emcure Pharmaceuticals Ltd rallied 36.57% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 2.64% during the same period.
